Clinical Trial Detail

NCT ID NCT02306850
Title Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors St. Louis University
Indications

melanoma

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.